

## PRESS RELEASE

Stockholm December 16, 2022

### **ADDvise receives order worth USD 2.1 million**

ADDvise Group AB's subsidiary Poly Pharmaceuticals Inc has received an order from Cochran Wholesale Pharmaceuticals, a generic pharmaceutical wholesale distributor serving the needs of independent pharmacies across the USA. The order is worth approximately USD 2.1 million. The order regards delivery of Folite, a folic acid dietary supplemental developed and manufactured by Poly Pharmaceuticals. Delivery will take place immediately.

#### **For further information, please contact:**

Rikard Akhtarzand, CEO  
+46 765-25 90 71  
rikard.akhtarzand@addvisigroup.se

#### **Important information:**

*This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 16, 2022, at 07:15 CET.*

#### **About ADDvise Group**

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at [www.addvisigroup.com](http://www.addvisigroup.com).